Digital Therapeutics Akili is a pioneering digital medicine company delivering therapies through a patented video game experience, indicating strong potential for partnerships with healthcare providers, payers, and pharma companies seeking non-pill treatment modalities.

ADHD and Neurology Focus With FDA clearance for EndeavorOTC targeting adults with ADHD and a pipeline spanning cognitive deficits in neurology and psychiatry, there are clear sales opportunities with clinics, hospitals, and insurers prioritizing ADHD, MDD, ASD and related cognitive conditions.

Strategic Partnerships Akili’s digital delivery model suggests collaboration potential with large pharmaceutical and biotech firms, research institutions, and digital health platforms to expand adoption, data sharing, and joint development of digital therapeutics.

Regulatory Progress Recent FDA clearance for an OTC digital treatment and ongoing investor activity indicate a favorable regulatory environment and market momentum, which can be leveraged in outreach to healthcare systems and distributors.

Growth Readiness With a mid-sized workforce and a multi-million-dollar revenue scale, Akili appears poised for sales expansion, channel partnerships, and enterprise deals with payers and health networks seeking innovative cognitive interventions.